D J Combs1, K J Gray2, S Schulman3, B T Bateman4. 1. Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: djcombs@bwh.harvard.edu. 2. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3. Divisions of Hemostasis and Thrombosis and Hematology and Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. 4. Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Women with preeclampsia may develop coagulopathy, predisposing to bleeding complications. Although guidelines and prior studies conflict, we hypothesized that in preeclampsia, abnormal coagulation test results are more common in women with thrombocytopenia or transaminase elevations and increase the transfusion risk. Our objectives were to investigate: 1. patterns of coagulation testing; 2. relationships between platelet count, transaminase level, and the risk of abnormal coagulation tests; 3. risk of bleeding complications; and 4. characteristics of patients with markedly abnormal coagulation parameters. METHODS: We conducted a cross-sectional study of deliveries of women with preeclampsia who had undergone activated partial thromboplastin time (aPTT) or international normalized ratio (INR) testing at one of two hospitals between 1994 and 2018. RESULTS: Of 10 699 women with preeclampsia, 3359 (32.7%) had coagulation testing performed and aPTT or INR elevations were present in 124 (3.7 %). Coagulation abnormalities were more common in women with thrombocytopenia or transaminase elevations (n=82) compared with those without (n=42) (6.7%, 95% CI 5.5 to 8.2 vs 1.8%, 95% CI 1.3 to 2.5). Transfusion was more common among women with abnormal coagulation parameters (n=124) compared with those without (n=39) (33.1 vs 7.0%, P <0.001). Among 26 patients with an aPTT ≥40 s or an INR ≥1.4, six required transfusion (all had placental abruption and disseminated intravascular coagulopathy). CONCLUSIONS: Coagulation testing was inconsistently performed in this cohort. Platelet counts and transaminase levels inadequately detected abnormal coagulation test results. Abnormal coagulation test results were associated with a markedly higher risk for red blood cell transfusion.
BACKGROUND: Women with preeclampsia may develop coagulopathy, predisposing to bleeding complications. Although guidelines and prior studies conflict, we hypothesized that in preeclampsia, abnormal coagulation test results are more common in women with thrombocytopenia or transaminase elevations and increase the transfusion risk. Our objectives were to investigate: 1. patterns of coagulation testing; 2. relationships between platelet count, transaminase level, and the risk of abnormal coagulation tests; 3. risk of bleeding complications; and 4. characteristics of patients with markedly abnormal coagulation parameters. METHODS: We conducted a cross-sectional study of deliveries of women with preeclampsia who had undergone activated partial thromboplastin time (aPTT) or international normalized ratio (INR) testing at one of two hospitals between 1994 and 2018. RESULTS: Of 10 699 women with preeclampsia, 3359 (32.7%) had coagulation testing performed and aPTT or INR elevations were present in 124 (3.7 %). Coagulation abnormalities were more common in women with thrombocytopenia or transaminase elevations (n=82) compared with those without (n=42) (6.7%, 95% CI 5.5 to 8.2 vs 1.8%, 95% CI 1.3 to 2.5). Transfusion was more common among women with abnormal coagulation parameters (n=124) compared with those without (n=39) (33.1 vs 7.0%, P <0.001). Among 26 patients with an aPTT ≥40 s or an INR ≥1.4, six required transfusion (all had placental abruption and disseminated intravascular coagulopathy). CONCLUSIONS: Coagulation testing was inconsistently performed in this cohort. Platelet counts and transaminase levels inadequately detected abnormal coagulation test results. Abnormal coagulation test results were associated with a markedly higher risk for red blood cell transfusion.
Authors: Wiebke Gogarten; Erik Vandermeulen; Hugo Van Aken; Sibylle Kozek; Juan V Llau; Charles M Samama Journal: Eur J Anaesthesiol Date: 2010-12 Impact factor: 4.330
Authors: Sonia Butalia; Francois Audibert; Anne-Marie Côté; Tabassum Firoz; Alexander G Logan; Laura A Magee; William Mundle; Evelyne Rey; Doreen M Rabi; Stella S Daskalopoulou; Kara A Nerenberg Journal: Can J Cardiol Date: 2018-03-01 Impact factor: 5.223
Authors: C M Salafia; J C Pezzullo; J A López-Zeno; S Simmens; V K Minior; A M Vintzileos Journal: Am J Obstet Gynecol Date: 1995-10 Impact factor: 8.661
Authors: Linden O Lee; Brian T Bateman; Sachin Kheterpal; Thomas T Klumpner; Michelle Housey; Michael F Aziz; Karen W Hand; Mark MacEachern; Christopher G Goodier; Jeffrey Bernstein; Melissa E Bauer Journal: Anesthesiology Date: 2017-06 Impact factor: 7.892
Authors: Samantha J Lain; Christine L Roberts; Ruth M Hadfield; Jane C Bell; Jonathan M Morris Journal: Aust N Z J Obstet Gynaecol Date: 2008-10 Impact factor: 2.100
Authors: C J Lockwood; M Paidas; W K Murk; U A Kayisli; A Gopinath; S J Huang; G Krikun; F Schatz Journal: Thromb Res Date: 2009-08-31 Impact factor: 3.944